CNS met development!!
Post-Embargo News Releases >Our Embargo Policy Print
Neratinib Plus Paclitaxel vs. Trastuzumab Plus Paclitaxel in Breast Cancer
JAMA Oncology
Original Investigation
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer
JAMA Oncology
Editorial
Neratinib in ERBB2-Positive Brain Metastases
EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, APRIL 14, 2016
Media Advisory: To contact corresponding study author Ahmad Awada. M.D., email
ahmad.awada@bordet.be. To contact editorial author Mark D. Pegram, M.D., call Krista Conger at 650-725-5371 or email
kristac@stanford.edu.
Related material: An audio interview will be live when the embargo lifts on the JAMA Oncology website.
To place an electronic embedded link in your story: Links will be live at the embargo time:
http://oncology.jamanetwork.com/arti...col.2016.0237; http://oncology.jamanetwork.com/arti...ncol.2016.0238
JAMA Oncology
While neratinib plus paclitaxel was not superior to trastuzumab plus paclitaxel as first-line treatment for ERBB2-positive metastatic breast cancer in terms of progression-free survival, the combination was associated with delayed onset and reduced frequency of central nervous system metastases, a finding that requires a larger study to confirm, according to an article published online by JAMA Oncology.
Metastatic ERBB2-positive breast cancer has a characteristic spread with most patients developing liver metastases and about half having poor prognosis with central nervous system involvement.
Ahmad Awada, M.D., of the Jules Bordet Institute, Brussels, and coauthors conducted a randomized clinical trial to examine progression-free survival in women with recurrent or metastatic ERBB2-positive breast cancer. They also examined secondary outcomes that included time to symptomatic or progressive central nervous system lesions and safety.
The NEfERT-T trial was conducted from 2009 through 2014 at 188 centers in 34 counties with 479 women, who were eligible if they had asymptomatic central nervous system lesions. The women were divided into two groups: 242 who received neratinib with paclitaxel and 237 who received trastuzumab plus paclitaxel.
Median progression-free survival was 12.9 months in both groups. However, the incidence of central nervous system recurrences was lower and the time to central nervous system metastases was delayed with neratinib plus paclitaxel, according to the results.
Diarrhea and gastrointestinal effects, such as nausea and vomiting, were the main adverse events associated with neratinib plus paclitaxel, which was consistent with the safety profile previously documented for this combination, the authors report.
The authors note the study protocol did not include screening for central nervous system metastases but rather identified them on the presentation of symptoms, which means it is likely that central nervous system events were underestimated. The accrual goal of the study also was reduced from 1,200 to 480 patients, which the authors note was a limitation with regard to efficacy, along with the exclusion of patients with progressive or symptomatic central nervous system disease.
“Neratinib in combination with paclitaxel was not superior in terms of PFS [progression-free survival] compared with trastuzumab-paclitaxel in the first-line treatment of women with ERBB2-positive metastatic breast cancer but showed similar efficacy and may delay the onset and reduce the frequency of CNS [central nervous system] metastases,” the authors conclude.
(JAMA Oncol. Published online April 14, 2016. doi:10.1001/jamaoncol.2016.0237. Available pre-embargo to the media at
http://media.jamanetwork.com.)
Editor’s Note: The study was sponsored by Wyeth, Pfizer and Puma Biotechnology, Inc. The article also includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Neratinib in ERBB2-Positive Brain Metastases
“The results presented herein by Awada et al are of sufficient interest to merit further investigation, preferably prospectively (with antidiarrheal prophylaxis), and in principle coupled with an extensive companion biomarker campaign designed to further characterize and classify those patients at highest risk for development of metastasis,” writes Mark D. Pegram, M.D., of the Stanford School of Medicine, California, in a related editorial.
(JAMA Oncol. Published online April 14, 2016. doi:10.1001/jamaoncol.2016.0238. Available pre-embargo to the media at
http://media.jamanetwork.com.)
Editor’s Note: The article contains conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
hot off press: for Stage IVs, neratinib+paclitxl =valent2 herceptin+pacli but delays
Linear Mode
